Related Experiment Video
Updated: Aug 10, 2026

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
The low potential for drug interactions with zanamivir
M J Daniel1, J M Barnett, B A Pearson
1Glaxo Wellcome Research and Development, Ware, England.
Zanamivir, an influenza antiviral, shows minimal interaction potential with other drugs. Studies indicate no significant metabolic or protein-binding interactions, suggesting safe coadministration in clinical settings.
Area of Science:
- Pharmacology
- Virology
Background:
- Zanamivir is a neuraminidase inhibitor for influenza A and B.
- Assessing drug interactions is crucial for safe clinical use.
Purpose of the Study:
- To evaluate the potential for zanamivir to interact with coadministered therapies.
- To determine if common drugs affect zanamivir's antiviral activity.
Main Methods:
- In vitro studies using human liver microsomes to assess metabolic interactions.
- In vivo rat models to examine cytochrome P450 enzyme expression.
- Protein binding assays and in vitro viral replication assays with coadministered drugs.
Main Results:
- Zanamivir did not affect cytochrome P450 enzyme expression or activity.
- Low binding of zanamivir to red blood cells and plasma proteins was observed.
- Commonly coadministered drugs did not interfere with zanamivir's in vitro antiviral potency.
Conclusions:
- Zanamivir has a low potential for metabolic or protein-binding interactions.
- Commonly used drugs are unlikely to affect zanamivir's antiviral efficacy.
- Clinical coadministration of zanamivir with other therapies is likely safe.
More Related Videos
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
10:16High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
Published on: October 30, 2021
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drug toxicity: Drug–Drug Interaction
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors